x |
Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2014
|
or | |
o | Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to |
Atrion Corporation
|
||
(Exact Name of Registrant as Specified in its Charter)
|
||
Delaware
|
63-0821819
|
|
(State or Other Jurisdiction of
|
(I.R.S. Employer
|
|
Incorporation or Organization) | Identification No.) | |
One Allentown Parkway, Allen, Texas 75002
|
||
(Address of Principal Executive Offices) (Zip Code)
|
||
(972) 390-9800
|
||
(Registrant’s Telephone Number, Including Area Code)
|
Large accelerated filer o | Accelerated filer x | Non-accelerated filer o | Smaller reporting company o |
Title of Each Class
|
Number of Shares Outstanding at
April 20, 2014
|
|
Common stock, Par Value $0.10 per share
|
1,969,463
|
2 | |
3 | |
For the Three months Ended | |
3 | |
4 | |
For the Three months Ended | |
5 | |
6 | |
8 | |
11 | |
12 | |
12 | |
12 | |
12 | |
12 | |
13 | |
14 | |
15 |
Three Months Ended | ||||||||
March 31,
|
||||||||
2014
|
2013
|
|||||||
(in thousands, except per share amounts)
|
||||||||
Revenues
|
$ |
36,419
|
$ |
33,493
|
||||
Cost of goods sold
|
19,031
|
17,784
|
||||||
Gross profit
|
17,388
|
15,709
|
||||||
Operating expenses:
|
||||||||
Selling
|
1,585
|
1,585
|
||||||
General and administrative
|
3,928
|
3,594
|
||||||
Research and development
|
1,175
|
1,130
|
||||||
6,688 | 6,309 | |||||||
Operating income
|
10,700 | 9,400 | ||||||
Interest income
|
300 | 350 | ||||||
Other income, net
|
1 | -- | ||||||
Income before provision for income taxes
|
11,001 | 9,750 | ||||||
Provision for income taxes
|
(3,800 | ) | (3,115 | ) | ||||
Net income
|
$ | 7,201 | $ | 6,635 | ||||
Net income per basic share
|
$ | 3.63 | $ | 3.28 | ||||
Weighted average basic shares outstanding
|
1,982 | 2,020 | ||||||
Net income per diluted share
|
$ | 3.61 | $ | 3.28 | ||||
Weighted average diluted shares outstanding
|
1,997 | 2,024 | ||||||
Dividends per common share
|
$ | 0.64 | $ | 0.56 |
March 31, | December 31, | |||||||
Assets
|
2014
|
2013
|
||||||
(in thousands)
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 17,196 | $ | 28,559 | ||||
Short-term investments
|
25,417 | 18,351 | ||||||
Accounts receivable
|
18,642 | 14,164 | ||||||
Inventories
|
26,326 | 26,266 | ||||||
Prepaid expenses and other current assets
|
1,008 | 1,603 | ||||||
Deferred income taxes
|
1,376 | 1,376 | ||||||
89,965 | 90,319 | |||||||
Long-term investments
|
12,375 | 10,069 | ||||||
Property, plant and equipment
|
133,753 | 130,504 | ||||||
Less accumulated depreciation and amortization
|
74,173 | 72,176 | ||||||
59,580 | 58,328 | |||||||
Other assets and deferred charges:
|
||||||||
Patents
|
2,740 | 2,808 | ||||||
Goodwill
|
9,730 | 9,730 | ||||||
Other
|
810 | 812 | ||||||
13,280 | 13,350 | |||||||
Total assets
|
$ | 175,200 | $ | 172,066 | ||||
Liabilities and Stockholders’ Equity
|
||||||||
Current liabilities: | ||||||||
Accounts payable and accrued liabilities
|
$ | 7,523 | $ | 8,511 | ||||
Accrued income and other taxes
|
4,113 | 853 | ||||||
11,636 | 9,364 | |||||||
Line of credit
|
-- | -- | ||||||
Other non-current liabilities
|
12,934 | 13,708 | ||||||
Stockholders’ equity: | ||||||||
Common stock, par value $0.10 per share; authorized 10,000 shares, issued 3,420 shares
|
342 | 342 | ||||||
Paid-in capital
|
31,967 | 31,592 | ||||||
Retained earnings
|
180,290 | 174,362 | ||||||
Treasury shares, 1,450 at March 31, 2014 and 1,435 at December 31, 2013, at cost
|
(61,969 | ) | (57,302 | ) | ||||
Total stockholders’ equity
|
150,630 | 148,994 | ||||||
Total liabilities and stockholders’ equity
|
$ | 175,200 | $ | 172,066 |
Three Months Ended
|
||||||||
March 31,
|
||||||||
2014 | 2013 | |||||||
(In thousands) | ||||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$ | 7,201 | $ | 6,635 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
2,265 | 2,141 | ||||||
Deferred income taxes
|
(546 | ) | (324 | ) | ||||
Stock-based compensation
|
367 | 355 | ||||||
Net change in accrued interest, premiums, and discounts on investments
|
3 | 196 | ||||||
Other
|
30 | 26 | ||||||
9,320 | 9,029 | |||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(4,478 | ) | (4,330 | ) | ||||
Inventories
|
(59 | ) | (268 | ) | ||||
Prepaid expenses
|
594 | 2,201 | ||||||
Other non-current assets
|
2 | (110 | ) | |||||
Accounts payable and accrued liabilities
|
(988 | ) | 144 | |||||
Accrued income and other taxes
|
3,260 | 1,416 | ||||||
Other non-current liabilities
|
(228 | ) | 3 | |||||
7,423 | 8,085 | |||||||
Cash flows from investing activities:
|
||||||||
Property, plant and equipment additions
|
(3,479 | ) | (1,573 | ) | ||||
Purchase of investments
|
(9,375 | ) | -- | |||||
Proceeds from maturities of investments
|
-- | 3,639 | ||||||
(12,854 | ) | 2,066 | ||||||
Cash flows from financing activities:
|
||||||||
Purchase of treasury stock
|
(4,667 | ) | (1,008 | ) | ||||
Dividends paid
|
(1,265 | ) | (1,130 | ) | ||||
(5,932 | ) | (2,138 | ) | |||||
Net change in cash and cash equivalents
|
(11,363 | ) | 8,013 | |||||
Cash and cash equivalents at beginning of period
|
28,559 | 7,999 | ||||||
Cash and cash equivalents at end of period
|
$ | 17,196 | $ | 16,012 | ||||
Cash paid for:
|
||||||||
Income taxes
|
$ | 924 | $ | 46 |
March 31,
|
December 31,
|
|||||||
2014
|
2013
|
|||||||
Raw materials
|
$ | 11,222 | $ | 10,744 | ||||
Work in process
|
6,971 | 6,246 | ||||||
Finished goods
|
8,133 | 9,276 | ||||||
Total inventories
|
$ | 26,326 | $ | 26,266 |
Three months ended March 31,
|
||||||||
2014 | 2013 | |||||||
(in thousands, except per share amounts) | ||||||||
Net income
|
$ | 7,201 | $ | $6,635 | ||||
Weighted average basic shares outstanding
|
1,982 | 2,020 | ||||||
Add: Effect of dilutive securities
|
15 | 4 | ||||||
Weighted average diluted shares outstanding
|
1,997 | 2,024 |
Earnings per share:
|
||||||||
Basic
|
$ | $3.63 | $ | $3.28 | ||||
Diluted
|
$ | $3.61 | $ | $3.28 |
Gross Unrealized
|
||||||||||||||||
Cost
|
Gains
|
Losses
|
Fair Value
|
|||||||||||||
Short-term Investments:
|
||||||||||||||||
Corporate bonds
|
$ | 25,417 | $ | 322 | $ | (15 | ) | $ | 25,724 | |||||||
Long-term Investments
|
||||||||||||||||
Corporate bonds
|
$ | 12,375 | $ | 3 | $ | (5 | ) | $ | 12,373 |
Three Months ended
March 31,
|
||||||||
2014
|
2013
|
|||||||
Fluid Delivery
|
$ | 15,237 | $ | 12,713 | ||||
Cardiovascular
|
11,029 | 10,151 | ||||||
Ophthalmology
|
5,184 | 5,795 | ||||||
Other
|
4,969 | 4,834 | ||||||
Total
|
$ | 36,419 | $ | 33,493 |
Period
|
Total Number of
Shares Purchased
|
Average Price
Paid per Share
|
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
|
Maximum
Number of
Shares that
May Yet Be
Purchased
Under the Plans
or Programs (1)
|
1/1/2014 through 1/31/2014
|
-
|
-
|
-
|
128,772
|
2/1/2014 through 2/28/2014
|
-
|
-
|
-
|
128,772
|
3/1/2014 through 3/31/2014
|
15,142
|
$ 308.23
|
15,142
|
113,630
|
Total
|
15,142
|
$ 308.23
|
15,142
|
113,630
|
(1)
|
On August 16, 2011, our Board of Directors approved a new stock repurchase program pursuant to which we can repurchase up to 200,000 shares of our common stock from time to time in open market or privately-negotiated transactions. This stock repurchase program has no expiration date but may be terminated by our Board of Directors at any time.
|
Exhibit
|
|
|
Number |
Description
|
|
31.1 |
Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
|
|
31.2 |
Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
|
|
32.1 |
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
|
|
32.2 |
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
|
|
101.INS |
XBRL Instance Document
|
|
101.SCH |
XBRL Taxonomy Extension Schema Document
|
|
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document
|
Atrion Corporation | |||
(Registrant) | |||
Date: May 5, 2014 | By: |
/s/ David A. Battat
|
|
David A. Battat
|
|||
President and
|
|||
Chief Executive Officer
|
|||
Date: May 5, 2014 | By: |
/s/ Jeffery Strickland
|
|
Jeffery Strickland
|
|||
Vice President and
|
|||
Chief Financial Officer
|
|||
(Principal Accounting and Financial Officer)
|
Exhibit
|
|
|
Number |
Description
|
|
31.1 |
Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer
|
|
31.2 |
Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer
|
|
32.1 |
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
|
|
32.2 |
Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002
|
|
101.INS |
XBRL Instance Document
|
|
101.SCH |
XBRL Taxonomy Extension Schema Document
|
|
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document
|